Comparative Pharmacology
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus VITRAKVI.
PAZOPANIB HYDROCHLORIDE vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-Kit). It also inhibits other kinases such as fibroblast growth factor receptors (FGFR-1, -3), cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor (c-Fms).
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Do not crush tablets.
100 mg orally twice daily
None Documented
None Documented
Terminal half-life is approximately 31 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily fecal (83%), with renal elimination accounting for <4% of the administered dose.
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor